1394033-54-5 Usage
Description
PF-05180999, also known as rucaparib, is a chemical compound that belongs to the class of poly(ADP-ribose) polymerase (PARP) inhibitors. It is a promising pharmaceutical candidate for the treatment of various cancers, particularly those associated with mutations in BRCA genes.
Used in Oncology:
PF-05180999 is used as a PARP inhibitor for the treatment of various cancers, particularly ovarian, breast, and prostate cancers in patients with specific genetic mutations. It works by inhibiting the enzyme PARP, which plays a role in repairing damaged DNA, ultimately leading to cancer cell death.
Used in Drug Development:
PF-05180999 is used as a research compound for the development of new cancer therapies targeting the PARP pathway. Its effectiveness in clinical trials has led to its approval for the treatment of certain types of ovarian and prostate cancers, and it is being investigated for its potential in other cancer types as well.
Check Digit Verification of cas no
The CAS Registry Mumber 1394033-54-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,9,4,0,3 and 3 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1394033-54:
(9*1)+(8*3)+(7*9)+(6*4)+(5*0)+(4*3)+(3*3)+(2*5)+(1*4)=155
155 % 10 = 5
So 1394033-54-5 is a valid CAS Registry Number.
1394033-54-5Relevant articles and documents
Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate
Helal, Christopher J.,Arnold, Eric,Boyden, Tracey,Chang, Cheng,Chappie, Thomas A.,Fisher, Ethan,Hajos, Mihaly,Harms, John F.,Hoffman, William E.,Humphrey, John M.,Pandit, Jayvardhan,Kang, Zhijun,Kleiman, Robin J.,Kormos, Bethany L.,Lee, Che-Wah,Lu, Jiemin,Maklad, Noha,McDowell, Laura,McGinnis, Dina,O'Connor, Rebecca E.,O'Donnell, Christopher J.,Ogden, Adam,Piotrowski, Mary,Schmidt, Christopher J.,Seymour, Patricia A.,Ueno, Hirokazu,Vansell, Nichole,Verhoest, Patrick R.,Yang, Edward X.
, p. 1001 - 1018 (2018/02/17)
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The analog PF-05180999 (30) was subsequen
